ScholarIQanswers from OpenAlex & ORCID
Michael Schenker
ResearcherPublications, citations & collaboration network
Michael Schenker is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michael Schenker have?
ScholarIQindexed works
Michael Schenker has 276 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michael Schenker have?
ScholarIQcitation count
Michael Schenker has 18,752 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michael Schenker?
ScholarIQh-index
Michael Schenker has an h-index of 48 in OpenAlex.
What is the i10-index of Michael Schenker?
ScholarIQi10-index
Michael Schenker has an i10-index of 102 in OpenAlex.
What is the ORCID of Michael Schenker?
ScholarIQorcid
The ORCID for Michael Schenker is on the source record.
What is the OpenAlex record for Michael Schenker?
ScholarIQopenalex
The OpenAlex for Michael Schenker is on the source record.
What are the most-cited papers on Michael Schenker?
ScholarIQmost cited works
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly, Jaffer A. Ajani, Jarosław Kużdżał, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Méndez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre, Hope E. Uronis, Elena Elimova, Cecile Grootscholten, Karen Geboes, Syed Zafar, Stephanie Snow, Andrew H. Ko, Kynan Feeney, Michael Schenker, Piotr Kocoń, Jenny Zhang, Lili Zhu, Ming Lei, Prianka Singh, Kaoru Kondo, James M. Cleary, Markus Moehler
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk, Christine Parkinson, Myong Cheol Lim, David M. O’Malley, Ana Oaknin, Michelle Wilson, Robert L. Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkıran, Olga Mikheeva, Oladapo Yeku, Anita Chudecka-Głaz, Michael Schenker, Ramey D. Littell, Tamar Safra, Hung‐Hsueh Chou, Mark A. Morgan, Vít Drochýtek, Joyce N. Barlin, Toon Van Gorp, Frederick R. Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile Catherine Collins, Kathleen N. Moore, Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
Martin Reck, Michael Schenker, Ki Hyeong Lee, Mariano Provencio, Makoto Nishio, Krzysztof Leśniewski-Kmak, Randeep Sangha, Samreen Ahmed, Judith Raimbourg, Kynan Feeney, R. Corre, Fábio Franke, Eduardo Richardet, John R. Penrod, Yong Yuan, Faith E. Nathan, Prabhu Bhagavatheeswaran, Michael DeRosa, Fiona Taylor, Rachael Lawrance, Julie R. Brahmer